Cargando…
Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: Is it feasible?
BACKGROUND: The increasing use of erythropoietins with long half-lives and the tendency to lengthen the administration interval to monthly injections call for raising awareness on the pharmacokinetics and risks of new erythropoietin stimulating agents (ESA). Their pharmacodynamic complexity and indi...
Autores principales: | Gabutti, Luca, Nobile, Filippo, Forni, Valentina, Rigamonti, Fabio, Weibel, Nadir, Burnier, Michel |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055807/ https://www.ncbi.nlm.nih.gov/pubmed/21332992 http://dx.doi.org/10.1186/1471-2369-12-11 |
Ejemplares similares
-
Effect of erythropoietin-stimulating agent on uremic inflammation
por: Tanaka, Yuri, et al.
Publicado: (2012) -
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
por: Hayat, Amir, et al.
Publicado: (2008) -
“Ideal” parathyroid hormone in erythropoietin‐stimulating agents‐resistant anemia
por: Ashraf, Bilal, et al.
Publicado: (2021) -
The Erythropoietin/Erythropoietin Receptor Signaling Pathway Promotes Growth and Invasion Abilities in Human Renal Carcinoma Cells
por: Wu, Pengjie, et al.
Publicado: (2012) -
Erythropoietin: a multimodal neuroprotective agent
por: Byts, Nadiya, et al.
Publicado: (2009)